Impact of Direct-Acting Antivirals on Recurrence of Hepatocellular Carcinoma after Curative Treatment.

Document Type : Original Article


1 Internal Medicine Department, Faculty of Medicine, Sohag University Hospital

2 Internal Medicine, Faculty of Medicine , sohag university, sohag, egypt

3 Department of Internal Medicine, faculty of medicine, Sohag University, Sohag, Egypt

4 Department of internal medicine, Sohag university hospital


Background: The contradictory findings of most of the research on the impact of DAAs on HCV-related HCC have sparked debate and controversy. As a result, the picture remains hazy for the time being, with significant heterogeneity.

Aim: To study the effect of DAAs on the recurrence of HCC in patients with chronic hepatitis C virus infection and a previous history of cured HCC.

Patients and Methods: 128 patients with chronic HCV infection with prior history of treated HCC by ablation or resection among them 63 patients received DAAs compared with 65 who did not receive DAAs and followed for at least one-year duration

Results: SVR was achieved in 90.47% in DAAs exposed patients with the recurrence of HCC in patients who received DAAs (34.29%) but when compared with a patient who did not receive DAAs, no statistically significant difference in the recurrence rate (34.29% vs 24.62%) with increased liver tissue stiffness, advanced child score and use of DAAs were independent risk factors of HCC recurrence.

Conclusion: DAAs do not increase the recurrence of HCC after curative treatment but also do not decrease it, further studies with longer follow-up duration are needed to assess the impact of DAAs on the recurrence of HCC.


Main Subjects